BE1023087B1 - Antigenes du cytomegalovirus et leurs utilisations - Google Patents

Antigenes du cytomegalovirus et leurs utilisations Download PDF

Info

Publication number
BE1023087B1
BE1023087B1 BE2016/5050A BE201605050A BE1023087B1 BE 1023087 B1 BE1023087 B1 BE 1023087B1 BE 2016/5050 A BE2016/5050 A BE 2016/5050A BE 201605050 A BE201605050 A BE 201605050A BE 1023087 B1 BE1023087 B1 BE 1023087B1
Authority
BE
Belgium
Prior art keywords
protein
complex
fragment
pentamer
cmv
Prior art date
Application number
BE2016/5050A
Other languages
English (en)
French (fr)
Other versions
BE1023087A1 (fr
Inventor
Andrea Carfi
Claudio Ciferri
Yi Xing
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Application granted granted Critical
Publication of BE1023087B1 publication Critical patent/BE1023087B1/fr
Publication of BE1023087A1 publication Critical patent/BE1023087A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/082—Hepadnaviridae (F), e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BE2016/5050A 2015-01-22 2016-01-22 Antigenes du cytomegalovirus et leurs utilisations BE1023087B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15152221.6 2015-01-22
EP15152221.6A EP3048114A1 (en) 2015-01-22 2015-01-22 Cytomegalovirus antigens and uses thereof

Publications (2)

Publication Number Publication Date
BE1023087B1 true BE1023087B1 (fr) 2016-11-18
BE1023087A1 BE1023087A1 (fr) 2016-11-18

Family

ID=52434568

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2016/5050A BE1023087B1 (fr) 2015-01-22 2016-01-22 Antigenes du cytomegalovirus et leurs utilisations

Country Status (24)

Country Link
US (2) US10167321B2 (enExample)
EP (3) EP3048114A1 (enExample)
JP (1) JP6717836B2 (enExample)
KR (1) KR20170100039A (enExample)
CN (1) CN107531761B (enExample)
AU (2) AU2016210548B2 (enExample)
BE (1) BE1023087B1 (enExample)
BR (1) BR112017015567A2 (enExample)
CA (1) CA2974041C (enExample)
DK (1) DK3247722T5 (enExample)
EA (1) EA038250B1 (enExample)
ES (1) ES2937959T3 (enExample)
FI (1) FI3247722T3 (enExample)
HR (1) HRP20230177T1 (enExample)
HU (1) HUE061175T2 (enExample)
IL (1) IL253366B (enExample)
LT (1) LT3247722T (enExample)
MX (1) MX382518B (enExample)
PL (1) PL3247722T3 (enExample)
PT (1) PT3247722T (enExample)
SG (1) SG11201705740UA (enExample)
SI (1) SI3247722T1 (enExample)
WO (1) WO2016116904A1 (enExample)
ZA (1) ZA201704912B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201802741T4 (tr) * 2010-05-14 2018-03-21 Univ Oregon Health & Science Rekombinant hcmv ve rhcmv vektörleri ve bunların kullanımları.
HUE037408T2 (hu) 2011-06-10 2018-08-28 Univ Oregon Health & Science CMV glikoproteinek és rekombináns vektorok
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
CN113528466B (zh) 2014-07-16 2024-12-24 俄勒冈健康与科学大学 包含外源抗原的人巨细胞病毒
JP6816031B2 (ja) 2015-02-10 2021-01-20 オレゴン ヘルス アンド サイエンス ユニバーシティ 非標準的なｃｄ８＋ｔ細胞応答を生成するのに有用な方法および組成物
MA42502A (fr) 2015-07-21 2018-05-30 Modernatx Inc Vaccins contre une maladie infectieuse
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
AU2016342045A1 (en) 2015-10-22 2018-06-07 Modernatx, Inc. Human cytomegalovirus vaccine
CN108474003A (zh) 2015-11-20 2018-08-31 俄勒冈健康与科学大学 包含微小rna识别元件的cmv载体
US11318197B2 (en) 2016-03-03 2022-05-03 Duke University Compositions and methods for inducing HIV-1 antibodies
US11246920B2 (en) 2016-03-03 2022-02-15 Duke University Compositions and methods for inducing HIV-1 antibodies
WO2018067580A1 (en) 2016-10-03 2018-04-12 Duke University Methods to identify immunogens by targeting improbable mutations
US10532099B2 (en) 2016-10-18 2020-01-14 Oregon Health & Science University Cytomegalovirus vectors eliciting T cells restricted by major histocompatibility complex E molecules
EP3528821A4 (en) 2016-10-21 2020-07-01 ModernaTX, Inc. HUMAN CYTOMEGALOVIRUS VACCINE
MA47515A (fr) 2017-02-16 2019-12-25 Modernatx Inc Compositions immunogènes très puissantes
CA3060019A1 (en) * 2017-04-19 2018-10-25 Glaxosmithkline Biologicals Sa Modified cytomegalovirus proteins and stabilized complexes
WO2019055807A1 (en) 2017-09-14 2019-03-21 Modernatx, Inc. RNA VACCINES AGAINST ZIKA VIRUS
WO2019070730A1 (en) 2017-10-02 2019-04-11 Duke University MOSAIC ENVELOPES OF HIV-1 TO INDUCE ADCC RESPONSES
WO2019169120A1 (en) 2018-02-28 2019-09-06 University Of Washington Self-asssembling nanostructure vaccines
WO2019195314A2 (en) 2018-04-03 2019-10-10 Sanofi Antigenic epstein barr virus polypeptides
EP3860650A4 (en) 2018-10-01 2022-06-29 Duke University Hiv-1 envelope stabilizing mutations
CN113271968B (zh) * 2018-10-17 2024-06-14 葛兰素史密丝克莱恩生物有限公司 经修饰的巨细胞病毒蛋白和稳定化的复合物
CN109627330A (zh) * 2018-12-18 2019-04-16 马鞍山史记动物健康管理有限公司 一种猪伪狂犬病毒高效价阳性血清制备方法
US12070495B2 (en) 2019-03-15 2024-08-27 Modernatx, Inc. HIV RNA vaccines
WO2021014385A1 (en) 2019-07-24 2021-01-28 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
TWI810589B (zh) * 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
WO2023144665A1 (en) 2022-01-28 2023-08-03 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
CN116162154B (zh) * 2022-10-21 2024-06-11 珠海泰诺麦博制药股份有限公司 抗人巨细胞病毒抗体及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014005959A1 (en) * 2012-07-06 2014-01-09 Novartis Ag Complexes of cytomegalovirus proteins

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
EP0945515A3 (en) 1989-11-06 2002-08-21 Cell Genesys, Inc. Production of proteins using homologous recombination
EP3031469B1 (en) 2006-06-07 2023-08-23 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
DK2352759T3 (en) * 2008-07-16 2017-12-18 Inst Res Biomedicine ANTIBODIES THAT NEUTRALIZE HUMAN CYTOMEGALOVIRUS AND USE THEREOF
WO2011027222A2 (en) 2009-09-02 2011-03-10 Novartis Ag Immunogenic compositions including tlr activity modulators
NZ606591A (en) 2010-07-06 2015-02-27 Novartis Ag Cationic oil-in-water emulsions
WO2012051211A2 (en) 2010-10-11 2012-04-19 Novartis Ag Antigen delivery platforms
MX350258B (es) 2011-07-06 2017-08-31 Novartis Ag Emulsiones cationicas de aceite en agua.
TWI570240B (zh) * 2011-09-09 2017-02-11 默沙東公司 作為細胞巨大病毒疫苗之條件式複製ｃｍｖ
CA2885145A1 (en) * 2012-10-30 2014-05-08 Redvax Gmbh Recombinant particle based vaccines against human cytomegalovirus infection
EP3083677B1 (en) 2013-12-20 2019-08-28 Novartis AG Novel eukaryotic cells and methods for recombinantly expressing a product of interest
JP6708548B2 (ja) 2013-12-20 2020-06-10 ノバルティス アーゲー 新規真核細胞および目的の生成物を組換え発現させるための方法
EP3015475A1 (en) 2014-10-31 2016-05-04 Novartis AG Mammalian cells expressing cytomegalovirus antigens
EP3047856A1 (en) 2015-01-23 2016-07-27 Novartis AG Cmv antigens and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014005959A1 (en) * 2012-07-06 2014-01-09 Novartis Ag Complexes of cytomegalovirus proteins

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CLAUDIO CIFERRI ET AL: "Structural and biochemical studies of HCMV gH/gL/gO and Pentamer reveal mutually exclusive cell entry complexes", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 112, no. 6, 26 January 2015 (2015-01-26), pages 1767 - 1772, XP055201992, ISSN: 0027-8424, DOI: 10.1073/pnas.1424818112 *
RYCKMAN BRENT J ET AL: "Characterization of the human cytomegalovirus gH/gL/UL128-131 complex that mediates entry into epithelial and endothelial cells", JOURNAL OF VIROLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 82, no. 1, 1 January 2008 (2008-01-01), pages 60 - 70, XP002519851, ISSN: 1098-5514, [retrieved on 20071017], DOI: 10.1128/JVI.01910-07 *
WEN YINGXIA ET AL: "Human cytomegalovirus gH/gL/UL128/UL130/UL131A complex elicits potently neutralizing antibodies in mice", VACCINE, ELSEVIER LTD, GB, vol. 32, no. 30, 14 May 2014 (2014-05-14), pages 3796 - 3804, XP029006326, ISSN: 0264-410X, DOI: 10.1016/J.VACCINE.2014.05.004 *

Also Published As

Publication number Publication date
EP3247722A1 (en) 2017-11-29
SG11201705740UA (en) 2017-08-30
MX382518B (es) 2025-03-13
WO2016116904A1 (en) 2016-07-28
CN107531761B (zh) 2022-01-14
CA2974041C (en) 2023-04-04
US20170369532A1 (en) 2017-12-28
JP2018504117A (ja) 2018-02-15
IL253366B (en) 2022-03-01
AU2016210548B2 (en) 2018-11-08
US20190276498A1 (en) 2019-09-12
BR112017015567A2 (pt) 2018-03-13
IL253366A0 (en) 2017-09-28
DK3247722T5 (da) 2024-10-07
HRP20230177T1 (hr) 2023-04-14
CA2974041A1 (en) 2016-07-28
MX2017009538A (es) 2017-11-02
ES2937959T3 (es) 2023-04-03
JP6717836B2 (ja) 2020-07-08
EA201791562A1 (ru) 2018-04-30
EA038250B1 (ru) 2021-07-29
ZA201704912B (en) 2018-12-19
HUE061175T2 (hu) 2023-05-28
KR20170100039A (ko) 2017-09-01
US10167321B2 (en) 2019-01-01
BE1023087A1 (fr) 2016-11-18
PT3247722T (pt) 2023-01-31
FI3247722T3 (fi) 2023-03-17
LT3247722T (lt) 2023-02-10
AU2018226521A1 (en) 2018-09-27
DK3247722T3 (da) 2023-01-30
AU2016210548A1 (en) 2017-08-10
PL3247722T3 (pl) 2023-03-20
EP4180056A1 (en) 2023-05-17
CN107531761A (zh) 2018-01-02
AU2018226521B2 (en) 2019-10-31
SI3247722T1 (sl) 2023-04-28
EP3048114A1 (en) 2016-07-27
EP3247722B1 (en) 2022-11-30

Similar Documents

Publication Publication Date Title
BE1023087B1 (fr) Antigenes du cytomegalovirus et leurs utilisations
BE1023213B1 (fr) Complexes issus du cytomegalovirus et leurs utilisations
EP2268816A1 (fr) Polynucléotides et polypeptides chimériques permettant la sécrétion d'un polypeptide d'intérêt en association avec des exosomes et leur utilisation pour la production de compositions immunogènes
CN113666990A (zh) 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用
CN113151184A (zh) 基于细胞膜展示冠状病毒免疫原以诱导中和抗体的方法
US20230174588A1 (en) A vaccine against sars-cov-2 and preparation thereof
KR20230008707A (ko) 코로나바이러스 치료용 백신 조성물
JP2025179041A (ja) 帯状疱疹ｍＲＮＡワクチン及びその調製方法と使用
JP2023549787A (ja) キメラコロナウイルススパイクタンパク質をコードする組換えベクターおよびその使用
US12398195B2 (en) Lamp constructs comprising allergens
JP2024545833A (ja) コロナウイルス科ウイルスによる感染症の処置または予防のためのウイルス様粒子
CA3221347A1 (en) Temperature-controllable, self-replicating rna vaccines for viral diseases
HK40087930A (en) Cytomegalovirus antigens and uses thereof
US20250177514A1 (en) Coronavirus antigen variants
EP4541806A1 (en) Modified coronavirus spike antigen protein and uses thereof
JP2024537847A (ja) ＣＯＶＩＤ１９ ｍＲＮＡワクチン
Andreasson Vaccination against Her2/neu-expressing cancer using chimeric virus-like particles

Legal Events

Date Code Title Description
MM Lapsed because of non-payment of the annual fee

Effective date: 20190131